Clinically pathogenic variants, particularly those in high-penetrance genes such as BRCA1/2 and APC, are of primary importance in cancer risk assessment and treatment (Preisler et al. 2021; Nepomuceno et al. 2024). The gene discussed is BRCA1; the disease is cancer.